This RSA section is an unofficial mirror, is not legal advice, and may be incomplete, outdated, or incorrectly processed.

RSA 126-Z:4 · Private Cause of Action

Title: X: PUBLIC HEALTH
Chapter: 126-Z · RIGHT TO TRY ACT
Status: current
Official source linked: Yes

Official source Copy section link

126-Z:4 Private Cause of Action. –

Copy link

Nothing in this chapter shall be construed to create a private cause of action against any person or entity except as specified in paragraph II.

Copy link

II.

Notwithstanding any provision of law to the contrary, any patient diagnosed with a terminal illness by a physician, and who has been treated, is being treated, or otherwise could be treated in New Hampshire with a drug, biologic, or device, and is affected by a violation of this chapter, or a health care facility or a health care provider involved in the treatment of the patient, shall be entitled to petition the superior court for injunctive relief and reasonable attorney's fees against any regulatory or law enforcement authority that violates this chapter. Source. 2016, 206:2, eff. June 6, 2016. 2024, 124:1, eff. Jan. 1, 2025. 2025, 304:4, eff. Jan. 1, 2026.

Copy link

Source note

Source. 2016, 206:2, eff. June 6, 2016. 2024, 124:1, eff. Jan. 1, 2025. 2025, 304:4, eff. Jan. 1, 2026.

Source history

2016, 206:2, eff. June 6, 2016
2024, 124:1, eff. Jan. 1, 2025
2025, 304:4, eff. Jan. 1, 2026

Related materials

Bill relationships

2026 HB1292 amend · effective 2027-01-01
l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati
2026 HB1292-FN amend · effective 2027-01-01
l and qualifying severe illness. This chapter shall be construed consistently with the general court's stated purpose. 5 New Section; Regenerative Stem Cell Therapies. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Regenerative Stem Cell Therapies. I. A physician may perform stem cell therapy that is not approved by the United States Food and Drug Administrati
2026 HB1809 reference · effective 2030-11-01
ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat
2026 HB1809-FN reference · effective 2030-11-01
ryptamine, found in certain mushrooms, but does not include synthetic or synthetic analogs of psilocybin. VI. “Qualifying patient” means a patient whom a provider, as defined by RSA 126-ZZ:1, II, has diagnosed a medically appropriate candidate for the use of medical psilocybin based on being diagnosed with a qualifying condition. VII. “Qualifying condition” means any of the following: (a) Major treat
2026 SB504 reference · effective 2027-01-01
nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t
2026 SB504-FN reference · effective 2027-01-01
nt, if applicable, that patient is liable for treatment expenses; and (6) A prominent statement that the patient is seeking treatment from an experimental treatment center under RSA 126-ZZ. II. “Experimental treatment” means the provision of a medical intervention by a health care provider involving an investigational drug, biologic, or device that has successfully completed phase one of a clinical t
2026 SB616 amend · effective 2027-07-01
r the right to try act. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Right to Try Act; Reporting Requirement. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Reporting Requirement. I. Any health care provider providing any type of care under this chapter shall report the following information, in writing, to
2026 SB616-FN amend · effective 2027-07-01
r the right to try act. Be it Enacted by the Senate and House of Representatives in General Court convened: 1 New Section; Right to Try Act; Reporting Requirement. Amend RSA 126-Z by inserting after section 8 the following new section: 126-Z:9 Reporting Requirement. I. Any health care provider providing any type of care under this chapter shall report the following information, in writing, to